ESMO Expert Consensus Statements on the Screening and Management of Financial Toxicity in Patients with Cancer
Published 15 April 2024 - ESMO Open
Authors: P.M. Carrera, G. Curigliano, D. Santini, L. Sharp, R.J. Chan, M. Pisu, F. Perrone, S. Karjalainen, G. Numico, N. Cherny, E. Winkler, M.L. Amador, M. Fitch, M. Lawler, F. Meunier, N. Khera, G. Pentheroudakis, D. Trapani, C.I. Ripamonti
Financial toxicity, defined as both the objective financial burden and subjective financial distress from a cancer diagnosis and its treatment, is a topic of interest in the assessment of the quality of life of patients with cancer and their families. Current evidence implicates financial toxicity in psychosocial, economic and other harms, leading to suboptimal cancer outcomes along the entire trajectory of diagnosis, treatment, supportive care, survivorship and palliation. This paper presents the results of a virtual consensus, based on the evidence base to date, on the screening and management of financial toxicity in patients with and beyond cancer organized by the European Society for Medical Oncology (ESMO) in 2022.